HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type i receptor

Kotaro Sakata; Mitsuko Hara; Takaho Terada; Noriyuki Watanabe; Daisuke Takaya; So Ichi Yaguchi; Takehisa Matsumoto; Tomokazu Matsuura; Mikako Shirouzu; Shigeyuki Yokoyama; Tokio Yamaguchi; Keiji Miyazawa; Hideki Aizaki; Tetsuro Suzuki; Takaji Wakita; Masaya Imoto; Soichi Kojima

doi:10.1038/srep03243

HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type i receptor

Kotaro Sakata, Mitsuko Hara, Takaho Terada, Noriyuki Watanabe, Daisuke Takaya, So Ichi Yaguchi, Takehisa Matsumoto, Tomokazu Matsuura, Mikako Shirouzu, Shigeyuki Yokoyama, Tokio Yamaguchi, Keiji Miyazawa, Hideki Aizaki, Tetsuro Suzuki, Takaji Wakita, Masaya Imoto, Soichi Kojima

研究成果: Article › 査読

32 被引用数 (Scopus)

抄録

Viruses sometimes mimic host proteins and hijack the host cell machinery. Hepatitis C virus (HCV) causes liver fibrosis, a process largely mediated by the overexpression of transforming growth factor (TGF)-β and collagen, although the precise underlying mechanism is unknown. Here, we report that HCV non-structural protein 3 (NS3) protease affects the antigenicity and bioactivity of TGF-β2 in (CAGA) 9 -Luc CCL64 cells and in human hepatic cell lines via binding to TGF-β type I receptor (TβRI). Tumor necrosis factor (TNF)-α facilitates this mechanism by increasing the colocalization of TβRI with NS3 protease on the surface of HCV-infected cells. An anti-NS3 antibody against computationally predicted binding sites for TβRI blocked the TGF-β mimetic activities of NS3 in vitro and attenuated liver fibrosis in HCV-infected chimeric mice. These data suggest that HCV NS3 protease mimics TGF-β2 and functions, at least in part, via directly binding to and activating TβRI, thereby enhancing liver fibrosis.

本文言語	English
論文番号	3243
ジャーナル	Scientific reports
巻	3
DOI	https://doi.org/10.1038/srep03243
出版ステータス	Published - 2013
外部発表	はい

ASJC Scopus subject areas

一般

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1038/srep03243

他のファイルとリンク

引用スタイル

Sakata, K., Hara, M., Terada, T., Watanabe, N., Takaya, D., Yaguchi, S. I., Matsumoto, T., Matsuura, T., Shirouzu, M., Yokoyama, S., Yamaguchi, T., Miyazawa, K., Aizaki, H., Suzuki, T., Wakita, T., Imoto, M., & Kojima, S. (2013). HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type i receptor. Scientific reports, 3, [3243]. https://doi.org/10.1038/srep03243

Sakata, K, Hara, M, Terada, T, Watanabe, N, Takaya, D, Yaguchi, SI, Matsumoto, T, Matsuura, T, Shirouzu, M, Yokoyama, S, Yamaguchi, T, Miyazawa, K, Aizaki, H, Suzuki, T, Wakita, T, Imoto, M & Kojima, S 2013, 'HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type i receptor', Scientific reports, vol. 3, 3243. https://doi.org/10.1038/srep03243

@article{f6fdec063abe4beda409ffb812bc1c35,

title = "HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type i receptor",

abstract = "Viruses sometimes mimic host proteins and hijack the host cell machinery. Hepatitis C virus (HCV) causes liver fibrosis, a process largely mediated by the overexpression of transforming growth factor (TGF)-β and collagen, although the precise underlying mechanism is unknown. Here, we report that HCV non-structural protein 3 (NS3) protease affects the antigenicity and bioactivity of TGF-β2 in (CAGA) 9 -Luc CCL64 cells and in human hepatic cell lines via binding to TGF-β type I receptor (TβRI). Tumor necrosis factor (TNF)-α facilitates this mechanism by increasing the colocalization of TβRI with NS3 protease on the surface of HCV-infected cells. An anti-NS3 antibody against computationally predicted binding sites for TβRI blocked the TGF-β mimetic activities of NS3 in vitro and attenuated liver fibrosis in HCV-infected chimeric mice. These data suggest that HCV NS3 protease mimics TGF-β2 and functions, at least in part, via directly binding to and activating TβRI, thereby enhancing liver fibrosis.",

author = "Kotaro Sakata and Mitsuko Hara and Takaho Terada and Noriyuki Watanabe and Daisuke Takaya and Yaguchi, {So Ichi} and Takehisa Matsumoto and Tomokazu Matsuura and Mikako Shirouzu and Shigeyuki Yokoyama and Tokio Yamaguchi and Keiji Miyazawa and Hideki Aizaki and Tetsuro Suzuki and Takaji Wakita and Masaya Imoto and Soichi Kojima",

note = "Funding Information: We are indebted to Mr. Kazushige Katsura and Ms. Chiemi Mishima-Tsumagari (RIKEN Systems and Structural Biology Center, Kanagawa, Japan; Division of Structural and Synthetic Biology, RIKEN Center for Life Science Technologies, Yokohama, Japan) for preparing and providing recombinant NS3, and Dr. Takashi Shimada, Dr. Chise Tateno, and Dr. Masakazu Kakuni (PhenixBio Co., Ltd., Hiroshima, Japan) for helpful discussions regarding the animal experiment. This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (23390202 to S.K.), and Grants for Collaborative Researchers from Industries (to K.S.), Program for Drug Discovery and Medical Technology Platforms (to S.K.), and Chemical Genomics Research Program (to S.K.) from RIKEN.",

year = "2013",

doi = "10.1038/srep03243",

language = "English",

volume = "3",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type i receptor

AU - Sakata, Kotaro

AU - Hara, Mitsuko

AU - Terada, Takaho

AU - Watanabe, Noriyuki

AU - Takaya, Daisuke

AU - Yaguchi, So Ichi

AU - Matsumoto, Takehisa

AU - Matsuura, Tomokazu

AU - Shirouzu, Mikako

AU - Yokoyama, Shigeyuki

AU - Yamaguchi, Tokio

AU - Miyazawa, Keiji

AU - Aizaki, Hideki

AU - Suzuki, Tetsuro

AU - Wakita, Takaji

AU - Imoto, Masaya

AU - Kojima, Soichi

N1 - Funding Information: We are indebted to Mr. Kazushige Katsura and Ms. Chiemi Mishima-Tsumagari (RIKEN Systems and Structural Biology Center, Kanagawa, Japan; Division of Structural and Synthetic Biology, RIKEN Center for Life Science Technologies, Yokohama, Japan) for preparing and providing recombinant NS3, and Dr. Takashi Shimada, Dr. Chise Tateno, and Dr. Masakazu Kakuni (PhenixBio Co., Ltd., Hiroshima, Japan) for helpful discussions regarding the animal experiment. This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (23390202 to S.K.), and Grants for Collaborative Researchers from Industries (to K.S.), Program for Drug Discovery and Medical Technology Platforms (to S.K.), and Chemical Genomics Research Program (to S.K.) from RIKEN.

PY - 2013

Y1 - 2013

N2 - Viruses sometimes mimic host proteins and hijack the host cell machinery. Hepatitis C virus (HCV) causes liver fibrosis, a process largely mediated by the overexpression of transforming growth factor (TGF)-β and collagen, although the precise underlying mechanism is unknown. Here, we report that HCV non-structural protein 3 (NS3) protease affects the antigenicity and bioactivity of TGF-β2 in (CAGA) 9 -Luc CCL64 cells and in human hepatic cell lines via binding to TGF-β type I receptor (TβRI). Tumor necrosis factor (TNF)-α facilitates this mechanism by increasing the colocalization of TβRI with NS3 protease on the surface of HCV-infected cells. An anti-NS3 antibody against computationally predicted binding sites for TβRI blocked the TGF-β mimetic activities of NS3 in vitro and attenuated liver fibrosis in HCV-infected chimeric mice. These data suggest that HCV NS3 protease mimics TGF-β2 and functions, at least in part, via directly binding to and activating TβRI, thereby enhancing liver fibrosis.

AB - Viruses sometimes mimic host proteins and hijack the host cell machinery. Hepatitis C virus (HCV) causes liver fibrosis, a process largely mediated by the overexpression of transforming growth factor (TGF)-β and collagen, although the precise underlying mechanism is unknown. Here, we report that HCV non-structural protein 3 (NS3) protease affects the antigenicity and bioactivity of TGF-β2 in (CAGA) 9 -Luc CCL64 cells and in human hepatic cell lines via binding to TGF-β type I receptor (TβRI). Tumor necrosis factor (TNF)-α facilitates this mechanism by increasing the colocalization of TβRI with NS3 protease on the surface of HCV-infected cells. An anti-NS3 antibody against computationally predicted binding sites for TβRI blocked the TGF-β mimetic activities of NS3 in vitro and attenuated liver fibrosis in HCV-infected chimeric mice. These data suggest that HCV NS3 protease mimics TGF-β2 and functions, at least in part, via directly binding to and activating TβRI, thereby enhancing liver fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=84888358608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888358608&partnerID=8YFLogxK

U2 - 10.1038/srep03243

DO - 10.1038/srep03243

M3 - Article

C2 - 24263861

AN - SCOPUS:84888358608

SN - 2045-2322

VL - 3

JO - Scientific Reports

JF - Scientific Reports

M1 - 3243

ER -

HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type i receptor

抄録

ASJC Scopus subject areas

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル